论文部分内容阅读
本文对３３例伴有左室肥厚（ＬＶＨ）的原发性高血压病人随机分为吲哚帕胺（Ｉｎｄａｐａｍｉｄｅ）治疗组１６例和随意治疗对照组１７例。治疗组在用药后２个月时血压降至１８．６／１２ｋＰａ者１２例，ＬＶＨ好转２例（２／１６），３个月时７／１６，４个月时１２／１６；观察到６个月时血压稳定在１８．６／１２ｋＰａ内，而心脏缩小例数未再增加。对照组用药２个月时血压降至１８．６／１２ｋＰａ者１３例，心脏缩小１／１７，３个月时３／１７；４个月时４／１７；观察到６个月血压稳定在１８．６／１２ｋＰａ内，而心脏缩小例数未再增加。治疗组与对照组比较血压下降无明显差异，而左室肥厚逆转有显著性差异（Ｐ＜０．０５）。
In this paper, 33 patients with essential hypertension with left ventricular hypertrophy (LVH) were randomly divided into indapamide (Indapamide) treatment group of 16 patients and 17 patients randomized control group. In the treatment group, the blood pressure dropped to 18.6 / 12kPa in 12 months and the LVH improved in 2 months (2/16) at 2 months after treatment. At the 6th month, Month blood pressure stabilized at 18.6 / 12kPa, and the number of cases of heart reduction did not increase. In the control group, blood pressure dropped to 18.6 / 12kPa at 2 months, 13 cases, 3/17 at 1 / 17,3 month, 4/17 at 4 months, and 6 months’ blood pressure was stable at 18 .6 / 12kPa, and the number of cases of heart reduction did not increase. There was no significant difference between the treatment group and the control group in blood pressure drop, while the reversal of left ventricular hypertrophy was significantly different (P <0.05).